e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Therapy of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
M. Faehling, S. Kuom, M. Leschke, M. Geissler, T. Kamp, R. Eckert (Esslingen, Wendlingen, Germany)
Source:
Annual Congress 2008 - Therapy of thoracic tumours
Session:
Therapy of thoracic tumours
Session type:
E-Communication Session
Number:
4307
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Faehling, S. Kuom, M. Leschke, M. Geissler, T. Kamp, R. Eckert (Esslingen, Wendlingen, Germany). Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice. Eur Respir J 2008; 32: Suppl. 52, 4307
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 241s
Year: 2007
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008
Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care.
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 753s
Year: 2006
Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003
Chemotherapy with oral vinorelbine for geriatric patients with advanced non-small cell lung cancer – preliminary results
Source: Eur Respir J 2006; 28: Suppl. 50, 752s
Year: 2006
Phase II study of cisplatin-vinorelbine sequenced by gemcitabine-vinorelbine in patients with unresectable non-small-cell lung cancer (NSCLC): preliminary results
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003
Smoking habits and erlotinib response in non-small-cell lung cancer (NSCLC) treatment
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2012; 39: 172-179
Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2011; 39: 172-179
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept